Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

Delayed Quote. Delayed  - 08/23 10:01:33 pm
97.27 USD   -0.74%
08/23 CVS HEALTH : Research Institute Study Shows Value in Tailoring Medic..
08/23 Report says Citizens' R.I. tax credits skyrocket from $3.4M to $1..
08/22 CVS HEALTH : teams up with Roca to provide at-risk women with career..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

CVS Caremark 4th-Quarter Profit Up 2.6% on Higher Sales

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 02:59pm CEST

--Debt refinancing costs weigh on bottom line, but sales broadly higher

--PBM, retail sales each rise, helping CVS report better-than-expected results

--Same-store sales growth exceeds monthly data posted by Walgreen, Rite Aid

(Updates with CEO interview comments, additional background and the latest stock quote, beginning in the first paragraph.)

 
   By John Kell 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as debt refinancing costs weighed on the bottom line, somewhat masking a strong performance for the company's pharmacy-benefits-management business and higher retail sales.

The drugstore retailer and PBM has now reported better-than-expected adjusted earnings for four consecutive quarters. Results in the fourth quarter were led by the PBM business, which saw revenue rise 17% to $18.6 billion, aided by new clients added to the network during the 2012 PBM selling season, higher drug costs and growth in the Medicare Part D program.

On the retail side, the top line jumped 5.1% to $16.3 billion as same-store sales grew 4%, growth that exceeds the monthly sales data posted by rivals Walgreen Co. (>> Walgreen Company) and Rite Aid Corp. (>> Rite Aid Corporation) in late 2012. Prescription volume growth was healthy, aided by client wins after Walgreen's contract dispute last year with fellow PBM Express Scripts Holding Co. (>> Express Scripts Holding Co) and stronger demand for flu-related prescriptions.

But CVS said pharmacy same-store sales were stung by higher usage of low-priced generics, which hurts the top line for drug store chains, though those products have a mixed benefit as they command higher margins.

An active flu season has helped drugstore chains somewhat mitigate the top-line dent caused by higher generic penetration, as consumers seek out vaccinations, order prescriptions and buy over-the-counter cough-and-cold medications. CVS Chief Executive Larry Merlo told Dow Jones Newswires that the company saw a "significant uptick" in flu activity by mid-December and strong demand through most of January.

Mr. Merlo said over the past two weeks, CVS has seen the severity of flu cases moderate. Still, the company has administered about 4.8 million flu shots so far this season, above last year's level.

Overall, CVS reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-related costs and other items, adjusted earnings from continuing operations were $1.14 in the latest quarter. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Gross margin expanded to 20.1% from 19.6%.

For the year, CVS now sees adjusted earnings from continuing operations of $3.86 to $4, a view that was lifted by two cents to reflect the debt refinancing.

CVS will face some lofty comparisons in 2013, due to strong demand for generics, particularly in the first half of the year. And after Walgreen inked a contract agreement with Express Scripts starting in September, the company has had some success winning back some customers it lost to competitors during the months-long spat, resulting in some lost business for CVS.

Shares were up 1.5% to $52.50 in premarket trading.

--Tess Stynes contributed to this article

Write to John Kell at john.kell@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORP
08/23 CVS HEALTH : Research Institute Study Shows Value in Tailoring Medication Adhere..
08/23 Report says Citizens' R.I. tax credits skyrocket from $3.4M to $11.9M in fisc..
08/22 CVS HEALTH : teams up with Roca to provide at-risk women with career training
08/18 CVS HEALTH : and the CVS Health Foundation Announce $100K Donation In Support of..
08/18 CVS HEALTH : Lipinski Announces Installation of Drop Box for Unwanted Prescripti..
08/18 CVS HEALTH : becomes latest Colorado pharmacy to offer opioid antidote without p..
08/17 CVS HEALTH : Makes Overdose-Reversal Drug Available Without A Prescription At Al..
08/17DJTarget Dims Outlook as Sales Struggle
08/17 CVS HEALTH : becomes latest Colorado pharmacy to offer opioid antidote without p..
08/16 CVS HEALTH : Survey Reveals Two in Five Americans Make Multiple Trips to get Ent..
More news
Sector news : Drug Retailers - NEC
08/22DJSINOPHARM GROUP : 1st Half Net Profit CNY2.53 Billion, Up 32% on Year
08/09DJPatient Survey Company Press Ganey to Sell Itself to Swedish Firm EQT
08/09DJValeant Posts a Loss and Says It Will Retool
08/02DJCARDINAL HEALTH : Warns of Quarterly Profit Decline
08/02DJCARDINAL HEALTH : Warns of Quarterly Profit Decline
More sector news : Drug Retailers - NEC
News from SeekingAlpha
08/22 Why I Didn't Buy Gilead, Apple Or 100 Others, Y'all - Part 3
08/21 MY PORTFOLIO UPDATE AND REVIEW OF 83 : Up 2 With Reynolds And Exelon, Down 1 Wit..
08/17 10 Dividend Growth Stocks For August 2016
08/16 SNIPPET ROUNDUP : Biogen Buy Rumours, CVS Cuts And Spark Gains On Shire's Loss
08/15 NIKE & STARBUCKS : That's What I Bought, Y'all - Part 2
Advertisement
Financials ($)
Sales 2016 179 904 M
EBIT 2016 10 782 M
Net income 2016 5 700 M
Debt 2016 24 998 M
Yield 2016 1,67%
P/E ratio 2016 18,95
P/E ratio 2017 15,76
EV / Sales 2016 0,72x
EV / Sales 2017 0,66x
Capitalization 104 489 M
More Financials
Chart CVS HEALTH CORP
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 111 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Stephen J. Gold Chief Information Officer & Executive Vice Preside
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP0.24%104 489
WALGREENS BOOTS ALLIAN..-2.84%89 551
EXPRESS SCRIPTS HOLDIN..-12.47%48 218
MCKESSON CORPORATION-1.82%43 707
CARDINAL HEALTH INC-7.98%26 172
AMERISOURCEBERGEN CORP..-14.42%19 058
More Results